Targovax doses first patient in Phase Ib/II trial of ONCOS-102 to treat MPM

Norwegian-based immuno-oncology company Targovax has dosed the first patient in the Phase Ib/II combination trial of a combination pemetrexed and cisplatin with ONCOS-102 to treat malignant pleural mesothelioma (MPM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news